Israel Active

Bar-Ilan University and Sheba Medical Center have established the $120 million Health Tech Valley biotech research institute. It will enable research into cancer, 3D organ printing, medical devices, sensors, robotics, AI medical data, personalized medicine, genetic engineering, and more.

Netanya’s Laniado Medical Center topped the Israeli Health Ministry’s National Patient Experience Survey. Even during the height of the war, 88% of Laniado’s patients were satisfied with their treatment. Every one of Israel’s 24 hospitals surveyed scored over 70%, with the average being 82%.

Two Israeli news media sites have just announced that, for the first time, an artificial cornea from Israel’s EndoArt was transplanted into a patient. The operation was performed at Israel’s Kaplan Medical Center.  But (see previously) Jerusalem’s Shaare Zedek Medical Center did the first one in 2022!

Israel’s Council for Higher Education has approved setting up a three-year pre-clinical medical school in Eilat. It aims to boost medical services and raise life expectancy in the area.

Hopefully, this will never be needed. The Helmsley Charitable Trust has donated $10 million to build an underground emergency hospital at Tel Aviv Sourasky Medical Center's (Ichilov) new Alrov Rehabilitation Tower. On level -5 it will have 250 beds, with plans for 150 more.

An Israeli-developed Pediatric AI Navigation and Decision Assistant (PANDA) has begun trials at Israel’s Schneider Children’s Medical Center. It answers clinical questions from the hospital’s knowledge base, so doctors can give children the most accurate treatment.

I24 broadcast its first “INNOV'NATION” program (Tues 9pm IST). It featured several interesting biotech companies. E.g., AION Labs (see previously) which now has nine startups in its portfolio. These include Cassidy Bio which is developing the first AI platform for faster, safer, gene editing.

Israel’s Techsomed (see previously) has received US FDA approval for its BioTraceIO360 software platform to be used to burn or freeze kidney tumors. The device was previously approved only for destroying liver tumors.

Israel’s PatenSee (see previously) has received US FDA Breakthrough Device Designation for its non-contact vascular access (VA) management technology designed for patients undergoing hemodialysis. Its imaging & AI warns of fistula deterioration.

Following 4 major US trials, the ES device from Israel’s Pulsenmore (see previously) has received US-FDA approval. It allows pregnant US women to carry out ultrasound fetal monitoring at home and will expand access to prenatal care in areas facing physician shortages.